Humana (HUM, Health insurers) Stock Valuation & Fair Value Significantly overvalued
Humana (HUM, Health insurers) trades at a current P/E of 39.6, about 134% above its historical normal valuation, with a forward growth estimate of 52.9% and a PEG of 0.75. Analysts' one-year estimates have been hit 73% of the time. Priced at its historical normal P/E of 16.9 on the same blended earnings, the 2026-10-09 close of $431.87 corresponds to about $184 a share. This is a valuation reference, not a price target.
No quality score is published for this company, which is normal for insurers, banks and REITs. This rating reflects valuation and forecast return, and for the top ratings, credit rating, growth and analyst accuracy.
- Price $433.50 at the 2026-10-12 close, 10.6% above the 20-day average ($391.96) and 11.3% above the 50-day ($389.41).
- RSI (14) at 66.4.
- 52-week range $162.46 to $433.50: the price is at the high and 166.8% above the low.
The Street vs SeerForecast
Wall Street's mean price target for HUM is $446.26 across 23 analysts, 2.9% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.
Valuation flags
- Overvalued by 134%
Verdict history
tickerseer's rating has been significantly overvalued since 2026-06-10.
Not every point was recorded live. Points marked recalculated are worked out from the metrics tickerseer archived that week.
Selected weeks: the first, the latest, and the cheapest and dearest.
Show all 38 weeks
Frequently asked questions
Is Humana stock overvalued?
At a current P/E of 39.6 versus its historical normal P/E of 16.9, Humana trades about 134% above its typical valuation, with a PEG of 0.75 on 52.9% forward growth. tickerseer currently rates it significantly overvalued.
What is Humana's fair value and PEG?
Humana trades at a current P/E of 39.6 against a historical normal P/E of 16.9, a PEG of 0.75, and a forward growth estimate of 52.9%. Priced at its historical normal P/E of 16.9 on the same blended earnings, the 2026-10-09 close of $431.87 corresponds to about $184 a share. This is a valuation reference, not a price target.
Has tickerseer's rating of Humana changed?
tickerseer's rating has been significantly overvalued since 2026-06-10.
What is the analyst price target for Humana?
The mean Wall Street price target for Humana is $446.26 across 23 analysts, 2.9% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.
Industry: Health insurers. Create a free account to see the full analysis: the SeerAI score, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.
Get the free weekly earnings preview
One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.
It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.